Related Experiment Video

Updated: Jan 4, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

370

Ceritinib-associated hyperglycemia in the Japanese Adverse Drug Event Report Database

Haruka Fujita1, Takaaki Murakami1, Fumiaki Tomoike2

  • 1Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Journal of Diabetes Investigation
|October 31, 2019
PubMed

Insights

Ceritinib, an anaplastic lymphoma kinase inhibitor, may increase the risk of hyperglycemia in non-small cell lung cancer patients. This finding suggests careful monitoring for elevated blood sugar is crucial when using ceritinib.

Area of Science:

  • Oncology
  • Pharmacovigilance
  • Endocrinology

Background:

  • Anaplastic lymphoma kinase (ALK) rearrangements drive non-small cell lung cancer (NSCLC) pathogenesis.
  • Ceritinib is an effective ALK inhibitor, even for patients with resistance to other ALK inhibitors.
  • A potential link between ceritinib and hyperglycemia requires investigation.

Purpose of the Study:

  • To investigate the association between ceritinib use and hyperglycemia.
  • To compare the risk of hyperglycemia with ceritinib versus other ALK inhibitors (crizotinib, alectinib).

Main Methods:

  • Disproportionality analysis of the Japanese Adverse Drug Event Report database (April 2004 - November 2018).
  • Calculation of reporting odds ratios (ROR) for hyperglycemia associated with ceritinib, crizotinib, and alectinib.
  • Analysis of ROR for ceritinib, excluding cases using antidiabetes agents.

Main Results:

  • Ceritinib showed a significantly increased reporting odds ratio (ROR) for hyperglycemia (2.25; 95% CI 1.24-4.08).
  • Crizotinib had a significantly decreased ROR (0.07; 95% CI 0.01-0.40), and alectinib showed no significant association (0.94; 95% CI 0.30-2.94).
  • Even without concomitant antidiabetes agents, ceritinib's ROR for hyperglycemia remained elevated (2.54; 95% CI 1.27-5.12).

Conclusions:

  • Ceritinib use is associated with an increased risk of hyperglycemia.
  • Healthcare providers should carefully monitor blood glucose levels in patients treated with ceritinib.
  • This finding highlights an important safety consideration for ceritinib in NSCLC treatment.
Keywords:
Anaplastic lymphoma kinaseCeritinibDrug-induced hyperglycemia

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.3K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
626
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
547
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
525
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
542
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
490
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
691